1Zhang XQ, Sorensen M, Fung M, et al. Synergistic in vitro antiretroviral activity of a humanized monoclonal anti-CD4 antibody ( TNX-355 ) and enfuvirtide ( T-20 ) [ J ]. Antimicrob Agents Chemother,2006,50(6) :2 231 -2 233.
2O' Brien S J, Moore JP. The effect of genetic variation in chemokines and their receptors on HIV transmission and progression to AIDS [ J ]. Immunol Rev,2000,177 : 99 - 111.
3Lalezari J, Goodrich J, DeJesus E,et al. Efficacy and safety of maraviroc plus optimized background therapy in viremia ART- experienced patients infected with CCR5-tropic HIV-1:24-week results of a Phase 2b/3 study in the US and Canada. Poster presented at the 14th Conference on Retroviruses and Opportunistic Infections ; 2007 February 25 - 28 ; Los Angeles, CA, USA.
4Nelson M, Fatkenheuer G, Konourina I. et al. Efficacy and safety of maraviroc plus optimized background therapy in viremia ART- experienced patients infected with CCR5-tropic HIV-1 in Europe, Australia, and North America:24-week results. Poster presented at the 14th Conference on Retroviruses and Opportunistic Infections; 2007 February 25-28 ; Los Angeles, CA, USA.
5Westby M, Lewis M, Whitcomb J, et al. Emergence of CXCR4- using human immunodeficiency virus type 1 ( HIV-1 ) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir[ J]. J Virol,2006,80 (10):4 909 -4 920.
6Markowitz M, Nguyen BY, Gotuzzo E, et al. Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor rahegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a d8-week controlled study [ J ]. J Acquir Immune Defic Syndr,2007,46 ( 2 ) : 125 - 133.
7Zolopa AR, Mullen M, Berger D, et al. The HIV integrase inhibitor GS-9137 has potent antiretroviral activity in treatment-experienced patients. 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles ,2007.
8Hammer SM, Eron JJ Jr, Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel[ J ]. JAMA ,2008 ,300 (5) :555 - 570.
9Lichtenstein K, Armon C, Buchacz K, et al. Early Uninterrupted ART is associated with improved outcomes and fewer toxicities in the HIV outpatient study (HOPS). In:Program and abstracts of the 13th Conference on Retroviruses and Opportunistic Infections;February 5 - 8,2006 ; Denver, Colo. Abstract 769.
10Vercauteren J, Deforche K, Theys K, et al. The incidence of muhidrug and full class resistance in HIV-1 infected patients is decreasing over time ( 2001 - 2006 ) in Portugal [ J]. Retrovirology, 2008,5 : 12.
2Dabis F,Newell ML,Hirschel B.HIV drugs for treatment,and for prevention[J].Lancet,2010,375(9731):2056-2057.
3Piacenti FJ.An update and review of antiretroviral therapy[J].Pharmacotherapy,2006,26(8):1111-1133.
4Sluis-Cremer N,Temiz NA,Bahar I.Conformational changes in HIV-1 reverse transcriptase induced by nonnucleoside reverse transcriptase inhibitor binding[J].Curr HIV Res,2004,2(4):323-332.
5Kim RJ,Wilson CG,Wabitsch M,et al.HIV protease inhibitorspecific alterations in human adipocyte differentiation and metabolism[J].Obesity (Silver Spring),2006,14(6):994-1002.
6Santhanam H,Goins M.Antiretroviral update:recent advances expand options for patients with HIV[J].Adv Nurse Pract,2004,12(11):53-54,56.
7de Mendoza C,Valer L,Ribera E,et al.Performance of six different ritonavir-boosted protease inhibitor-based regimens in heavily antiretroviral-experienced HIV-infected patients[J].HIV Clin Trials,2006,7(4):163-171.
8Root M J,Hamer DH.Targeting therapeutics to an exposed and conserved binding element of the HIV-1 fusion protein[J].Proc Notl Acad Sci U S A,2003,100(9):5016-5021.
9Strizki JM,Tremblay C,Xu S,et al.Discovery and characterization of vicriviroc (SCH 417690),a CCR5 antagonist with potent activity against human immunodeficiency virus type 1[J].Antimicrob Agents Chemother,2005,49(12):4911-4919.
10DeJesus E,Berger D,Markowitz M,et al.Antiviral activity,pharmacokinetics,and dose response of the HIV-1 integrase inhibitor GS-9137(JTK-303) in treatment-naive and treatment-experienced patients[J].J Acquir Immune Defic Syndr,2006,43(1):1-5.
